

Qing Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8863253/publications.pdf>

Version: 2024-02-01

58
papers

1,301
citations

430874

18
h-index

377865

34
g-index

63
all docs

63
docs citations

63
times ranked

1787
citing authors

#	ARTICLE	IF	CITATIONS
1	Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19. <i>Cardiovascular Research</i> , 2020, 116, 353-367.	3.8	213
2	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	1.6	168
3	Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. <i>Stem Cell Research and Therapy</i> , 2019, 10, 300.	5.5	90
4	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	86
5	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. <i>Oncotarget</i> , 2016, 7, 60647-60656.	1.8	63
6	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	7.0	60
7	RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. <i>Journal of Clinical Oncology</i> , 2021, 39, 1022-1022.	1.6	48
8	In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. <i>Frontiers in Oncology</i> , 2021, 11, 774577.	2.8	46
9	Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia/Reperfusion injury. <i>Theranostics</i> , 2020, 10, 11754-11774.	10.0	37
10	New strategies for improving stem cell therapy in ischemic heart disease. <i>Heart Failure Reviews</i> , 2016, 21, 737-752.	3.9	34
11	Optimization of Timing and Times for Administration of Atorvastatin-Pretreated Mesenchymal Stem Cells in a Preclinical Model of Acute Myocardial Infarction. <i>Stem Cells Translational Medicine</i> , 2019, 8, 1068-1083.	3.3	34
12	Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1. <i>Frontiers in Pharmacology</i> , 2017, 8, 775.	3.5	33
13	Tongxinluo exerts protective effects via anti-apoptotic and pro-autophagic mechanisms by activating AMPK pathway in infarcted rat hearts. <i>Experimental Physiology</i> , 2017, 102, 422-435.	2.0	31
14	Age-Related Disparity in Immediate Prognosis of Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. <i>PLoS ONE</i> , 2015, 10, e0128345.	2.5	27
15	Quantitative Proteomics Analysis of Ischemia/Reperfusion Injury-Modulated Proteins in Cardiac Microvascular Endothelial Cells and the Protective Role of Tongxinluo. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 1503-1518.	1.6	25
16	The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. <i>International Journal of Cancer</i> , 2018, 143, 184-189.	5.1	25
17	Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 67-77.	2.5	24
18	The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nationwide multi-center retrospective study across China. <i>International Journal of Cancer</i> , 2016, 139, 2687-2697.	5.1	21

#	ARTICLE	IF	CITATIONS
19	Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study. <i>Oncology Letters</i> , 2019, 17, 4768-4778.	1.8	16
20	Young breast cancer patients who develop distant metastasis after surgery have better survival outcomes compared with elderly counterparts. <i>Oncotarget</i> , 2017, 8, 44851-44859.	1.8	15
21	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). <i>Cancer</i> , 2020, 126, 3867-3882.	4.1	15
22	Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life. <i>Annals of Surgical Oncology</i> , 2020, 27, 1025-1033.	1.5	15
23	Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4699-4706.	1.9	14
24	Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy. <i>Chinese Journal of Cancer</i> , 2018, 37, 4.	4.9	13
25	Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. <i>International Journal of Cancer</i> , 2018, 143, 2499-2504.	5.1	12
26	Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092599.	3.2	11
27	Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. <i>International Journal of Cancer</i> , 2020, 147, 3490-3499.	5.1	11
28	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. <i>Clinical Breast Cancer</i> , 2021, 21, e497-e505.	2.4	10
29	Efficacy and safety of duloxetine in Chinese breast cancer patients with paclitaxel-induced peripheral neuropathy. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2017, 29, 411-418.	2.2	9
30	Effects of the Endophytic Fungus MF23 on <i>Dendrobium nobile</i> Lindl. in an Artificial Primary Environment. <i>ACS Omega</i> , 2021, 6, 10047-10053.	3.5	9
31	Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2019, 31, 759-770.	2.2	9
32	Molecular analysis of polysaccharide accumulation in <i>Dendrobium nobile</i> infected with the mycorrhizal fungus <i>Mycena</i> sp.. <i>RSC Advances</i> , 2017, 7, 25872-25884.	3.6	8
33	Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 485-496.	2.2	8
34	Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. <i>Cancer Biology and Medicine</i> , 2021, 18, 875-887.	3.0	7
35	A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4077-4077.	1.6	7
36	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 591-599.	3.6	6

#	ARTICLE	IF	CITATIONS
37	A randomized phase III trial comparing dose-dense epirubicin and cyclophosphamide (ECdd) followed by paclitaxel (T) with paclitaxel plus carboplatin (PCdd) as adjuvant chemotherapy for early triple-negative breast cancer patients with high-recurrence risk.. Journal of Clinical Oncology, 2019, 37, 528-528.	1.6	6
38	Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up. Breast Cancer Research and Treatment, 2022, 191, 97-105.	2.5	6
39	Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage I to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. International Journal of Cancer, 2022, 151, 578-589.	5.1	6
40	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer. Breast Cancer Research and Treatment, 2022, 193, 381-392.	2.5	5
41	Phase I study of QLNC120, a novel EGFR and HER2 kinase inhibitor, in pre-treated patients with HER2-overexpressing advanced breast cancer. Oncotarget, 2017, 8, 36750-36760.	1.8	3
42	The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. Clinical Breast Cancer, 2019, 19, e370-e375.	2.4	3
43	Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China. Breast, 2022, 61, 129-135.	2.2	3
44	Primary Trastuzumab Resistance After (Neo)adjuvant Trastuzumab-containing Treatment for Patients With HER2-positive Breast Cancer in Real-world Practice. Clinical Breast Cancer, 2021, 21, 191-198.	2.4	2
45	Differential response of neoadjuvant chemotherapy with taxane-carboplatin versus taxane-epirubicin in patients with locally advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 1105-1105.	1.6	2
46	Phase I safety and pharmacokinetic study of ciptinib, an original dual tyrosine kinase inhibitor. Thoracic Cancer, 2018, 9, 1041-1047.	1.9	1
47	Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis. Annals of Translational Medicine, 2021, 9, 109-109.	1.7	1
48	A real-world retrospective study of apatinib plus chemotherapy in metastatic breast cancer.. Journal of Clinical Oncology, 2017, 35, e12507-e12507.	1.6	1
49	Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1034-1034.	1.6	1
50	Abstract PS6-28: Development and external validation of a clinical nomogram for individually predicting survival of metastatic breast carcinoma. , 2021, , .		0
51	Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.. Journal of Clinical Oncology, 2021, 39, e12586-e12586.	1.6	0
52	Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes.. Journal of Clinical Oncology, 2014, 32, 1042-1042.	1.6	0
53	Phase II study of apatinib plus vinorelbine, a novel combination of all-oral regimen in heavily pretreated patients with metastatic HER2-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1123-TPS1123.	1.6	0
54	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center.. Journal of Clinical Oncology, 2019, 37, e12590-e12590.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Progression-free survival as a predictor of overall survival in patients with advanced breast cancer: A real-world study from the China National Cancer Center and validation in the Memorial Sloan Kettering Cancer Center Cohort.. <i>Journal of Global Oncology</i> , 2019, 5, 88-88.	0.5	0
56	Abstract P1-16-06: In real world, a high percentage of premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer receive chemotherapy as first-line treatment: A study of the National Cancer Center, China. <i>Cancer Research</i> , 2022, 82, P1-16-06-P1-16-06.	0.9	0
57	Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice. <i>Frontiers in Oncology</i> , 2022, 12, 867583.	2.8	0
58	Peripheral lipidomics analyses with ensemble machine learning predict response to neoadjuvant therapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 582-582.	1.6	0